Amundi Index Solutions - Amundi EURO STOXX 50 UCITS ETF-D EUR
Amundi Index Solutions - Amundi EURO STOXX 50 UCITS ETF-D EUR (CD5.PA) Stock Competitors & Peer Comparison
See (CD5.PA) competitors and their performances in Stock Market.
Peer Comparison Table: Asset Management Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CD5.PA | €86.14 | -0.13% | 3.5B | 16.65 | €5.17 | +2.53% |
| IWDA.AS | €103.81 | +0.85% | 99.3B | N/A | N/A | N/A |
| VUSA.AS | €104.22 | +1.14% | 61.4B | N/A | N/A | +1.07% |
| VWRL.AS | €132.14 | +0.87% | 36.4B | N/A | N/A | +1.55% |
| SP5C.PA | €395.46 | +1.20% | 20.2B | 27.25 | €14.51 | N/A |
| SP5H.PA | €315.50 | +0.22% | 20B | 27.54 | €11.45 | +1.98% |
| IUSA.AS | €54.78 | +1.17% | 16.4B | N/A | N/A | +1.04% |
| ISFA.AS | €10.19 | +0.18% | 14.8B | N/A | N/A | +3.47% |
| AMUN.PA | €70.15 | -0.14% | 14.3B | 11.01 | €6.37 | +6.06% |
| HAL.AS | €124.80 | +0.16% | 11.3B | 9.32 | €13.39 | +2.32% |
Stock Comparison
CD5.PA vs IWDA.AS Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, IWDA.AS has a market cap of 99.3B. Regarding current trading prices, CD5.PA is priced at €86.14, while IWDA.AS trades at €103.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas IWDA.AS's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is +0.00%, compared to IWDA.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to IWDA.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check IWDA.AS's competition here
CD5.PA vs VUSA.AS Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, VUSA.AS has a market cap of 61.4B. Regarding current trading prices, CD5.PA is priced at €86.14, while VUSA.AS trades at €104.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas VUSA.AS's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is +0.00%, compared to VUSA.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to VUSA.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check VUSA.AS's competition here
CD5.PA vs VWRL.AS Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, VWRL.AS has a market cap of 36.4B. Regarding current trading prices, CD5.PA is priced at €86.14, while VWRL.AS trades at €132.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas VWRL.AS's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is +0.00%, compared to VWRL.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to VWRL.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check VWRL.AS's competition here
CD5.PA vs SP5C.PA Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, SP5C.PA has a market cap of 20.2B. Regarding current trading prices, CD5.PA is priced at €86.14, while SP5C.PA trades at €395.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas SP5C.PA's P/E ratio is 27.25. In terms of profitability, CD5.PA's ROE is +0.00%, compared to SP5C.PA's ROE of N/A. Regarding short-term risk, CD5.PA is more volatile compared to SP5C.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check SP5C.PA's competition here
CD5.PA vs SP5H.PA Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, SP5H.PA has a market cap of 20B. Regarding current trading prices, CD5.PA is priced at €86.14, while SP5H.PA trades at €315.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas SP5H.PA's P/E ratio is 27.54. In terms of profitability, CD5.PA's ROE is +0.00%, compared to SP5H.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to SP5H.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check SP5H.PA's competition here
CD5.PA vs IUSA.AS Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, IUSA.AS has a market cap of 16.4B. Regarding current trading prices, CD5.PA is priced at €86.14, while IUSA.AS trades at €54.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas IUSA.AS's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is +0.00%, compared to IUSA.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to IUSA.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check IUSA.AS's competition here
CD5.PA vs ISFA.AS Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, ISFA.AS has a market cap of 14.8B. Regarding current trading prices, CD5.PA is priced at €86.14, while ISFA.AS trades at €10.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas ISFA.AS's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is +0.00%, compared to ISFA.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to ISFA.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check ISFA.AS's competition here
CD5.PA vs AMUN.PA Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, AMUN.PA has a market cap of 14.3B. Regarding current trading prices, CD5.PA is priced at €86.14, while AMUN.PA trades at €70.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas AMUN.PA's P/E ratio is 11.01. In terms of profitability, CD5.PA's ROE is +0.00%, compared to AMUN.PA's ROE of +0.11%. Regarding short-term risk, CD5.PA is less volatile compared to AMUN.PA. This indicates potentially lower risk in terms of short-term price fluctuations for CD5.PA.Check AMUN.PA's competition here
CD5.PA vs HAL.AS Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, HAL.AS has a market cap of 11.3B. Regarding current trading prices, CD5.PA is priced at €86.14, while HAL.AS trades at €124.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas HAL.AS's P/E ratio is 9.32. In terms of profitability, CD5.PA's ROE is +0.00%, compared to HAL.AS's ROE of +0.08%. Regarding short-term risk, CD5.PA is more volatile compared to HAL.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check HAL.AS's competition here
CD5.PA vs IMEU.AS Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, IMEU.AS has a market cap of 10.3B. Regarding current trading prices, CD5.PA is priced at €86.14, while IMEU.AS trades at €34.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas IMEU.AS's P/E ratio is 17.91. In terms of profitability, CD5.PA's ROE is +0.00%, compared to IMEU.AS's ROE of N/A. Regarding short-term risk, CD5.PA is more volatile compared to IMEU.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check IMEU.AS's competition here
CD5.PA vs CSH2.PA Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, CSH2.PA has a market cap of 9.9B. Regarding current trading prices, CD5.PA is priced at €86.14, while CSH2.PA trades at €107.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas CSH2.PA's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is +0.00%, compared to CSH2.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to CSH2.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check CSH2.PA's competition here
CD5.PA vs PSH.AS Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, PSH.AS has a market cap of 9.4B. Regarding current trading prices, CD5.PA is priced at €86.14, while PSH.AS trades at €51.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas PSH.AS's P/E ratio is 4.41. In terms of profitability, CD5.PA's ROE is +0.00%, compared to PSH.AS's ROE of +0.11%. Regarding short-term risk, CD5.PA is less volatile compared to PSH.AS. This indicates potentially lower risk in terms of short-term price fluctuations for CD5.PA.Check PSH.AS's competition here
CD5.PA vs WLD.PA Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, WLD.PA has a market cap of 9.4B. Regarding current trading prices, CD5.PA is priced at €86.14, while WLD.PA trades at €354.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas WLD.PA's P/E ratio is 23.74. In terms of profitability, CD5.PA's ROE is +0.00%, compared to WLD.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to WLD.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check WLD.PA's competition here
CD5.PA vs WLDH.PA Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, WLDH.PA has a market cap of 9.3B. Regarding current trading prices, CD5.PA is priced at €86.14, while WLDH.PA trades at €225.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas WLDH.PA's P/E ratio is 23.97. In terms of profitability, CD5.PA's ROE is +0.00%, compared to WLDH.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to WLDH.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check WLDH.PA's competition here
CD5.PA vs GBLB.BR Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, GBLB.BR has a market cap of 9.2B. Regarding current trading prices, CD5.PA is priced at €86.14, while GBLB.BR trades at €76.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas GBLB.BR's P/E ratio is 318.75. In terms of profitability, CD5.PA's ROE is +0.00%, compared to GBLB.BR's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to GBLB.BR. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check GBLB.BR's competition here
CD5.PA vs MEUD.PA Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, MEUD.PA has a market cap of 9.1B. Regarding current trading prices, CD5.PA is priced at €86.14, while MEUD.PA trades at €262.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas MEUD.PA's P/E ratio is 17.55. In terms of profitability, CD5.PA's ROE is +0.00%, compared to MEUD.PA's ROE of N/A. Regarding short-term risk, CD5.PA is more volatile compared to MEUD.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check MEUD.PA's competition here
CD5.PA vs SOF.BR Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, SOF.BR has a market cap of 8.9B. Regarding current trading prices, CD5.PA is priced at €86.14, while SOF.BR trades at €270.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas SOF.BR's P/E ratio is 6.73. In terms of profitability, CD5.PA's ROE is +0.00%, compared to SOF.BR's ROE of +0.14%. Regarding short-term risk, CD5.PA is more volatile compared to SOF.BR. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check SOF.BR's competition here
CD5.PA vs CBUG.AS Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, CBUG.AS has a market cap of 8.3B. Regarding current trading prices, CD5.PA is priced at €86.14, while CBUG.AS trades at €4.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas CBUG.AS's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is +0.00%, compared to CBUG.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to CBUG.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check CBUG.AS's competition here
CD5.PA vs I500.AS Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, I500.AS has a market cap of 7.8B. Regarding current trading prices, CD5.PA is priced at €86.14, while I500.AS trades at €10.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas I500.AS's P/E ratio is 27.86. In terms of profitability, CD5.PA's ROE is +0.00%, compared to I500.AS's ROE of N/A. Regarding short-term risk, CD5.PA is more volatile compared to I500.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check I500.AS's competition here
CD5.PA vs I50D.AS Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, I50D.AS has a market cap of 7.7B. Regarding current trading prices, CD5.PA is priced at €86.14, while I50D.AS trades at €7.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas I50D.AS's P/E ratio is 28.16. In terms of profitability, CD5.PA's ROE is +0.00%, compared to I50D.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to I50D.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check I50D.AS's competition here
CD5.PA vs GOLD.PA Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, GOLD.PA has a market cap of 7B. Regarding current trading prices, CD5.PA is priced at €86.14, while GOLD.PA trades at €113.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas GOLD.PA's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is +0.00%, compared to GOLD.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to GOLD.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check GOLD.PA's competition here
CD5.PA vs LCWD.PA Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, LCWD.PA has a market cap of 7B. Regarding current trading prices, CD5.PA is priced at €86.14, while LCWD.PA trades at €19.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas LCWD.PA's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is +0.00%, compared to LCWD.PA's ROE of N/A. Regarding short-term risk, CD5.PA is more volatile compared to LCWD.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check LCWD.PA's competition here
CD5.PA vs IWRD.AS Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, IWRD.AS has a market cap of 6.9B. Regarding current trading prices, CD5.PA is priced at €86.14, while IWRD.AS trades at €75.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas IWRD.AS's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is +0.00%, compared to IWRD.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to IWRD.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check IWRD.AS's competition here
CD5.PA vs CEUU.AS Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, CEUU.AS has a market cap of 6.8B. Regarding current trading prices, CD5.PA is priced at €86.14, while CEUU.AS trades at €10.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas CEUU.AS's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is +0.00%, compared to CEUU.AS's ROE of N/A. Regarding short-term risk, CD5.PA is more volatile compared to CEUU.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check CEUU.AS's competition here
CD5.PA vs ECRP.PA Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, ECRP.PA has a market cap of 6.3B. Regarding current trading prices, CD5.PA is priced at €86.14, while ECRP.PA trades at €53.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas ECRP.PA's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is +0.00%, compared to ECRP.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to ECRP.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check ECRP.PA's competition here
CD5.PA vs CC4.PA Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, CC4.PA has a market cap of 6.3B. Regarding current trading prices, CD5.PA is priced at €86.14, while CC4.PA trades at €225.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas CC4.PA's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is +0.00%, compared to CC4.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to CC4.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check CC4.PA's competition here
CD5.PA vs VHYL.AS Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, VHYL.AS has a market cap of 6.3B. Regarding current trading prices, CD5.PA is priced at €86.14, while VHYL.AS trades at €64.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas VHYL.AS's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is +0.00%, compared to VHYL.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to VHYL.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check VHYL.AS's competition here
CD5.PA vs SJPE.AS Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, SJPE.AS has a market cap of 6.3B. Regarding current trading prices, CD5.PA is priced at €86.14, while SJPE.AS trades at €10.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas SJPE.AS's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is +0.00%, compared to SJPE.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to SJPE.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check SJPE.AS's competition here
CD5.PA vs SJPD.AS Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, SJPD.AS has a market cap of 6.3B. Regarding current trading prices, CD5.PA is priced at €86.14, while SJPD.AS trades at €6.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas SJPD.AS's P/E ratio is 14.98. In terms of profitability, CD5.PA's ROE is +0.00%, compared to SJPD.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to SJPD.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check SJPD.AS's competition here
CD5.PA vs 500.PA Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, 500.PA has a market cap of 6.1B. Regarding current trading prices, CD5.PA is priced at €86.14, while 500.PA trades at €108.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas 500.PA's P/E ratio is 27.25. In terms of profitability, CD5.PA's ROE is +0.00%, compared to 500.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to 500.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check 500.PA's competition here
CD5.PA vs AEME.PA Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, AEME.PA has a market cap of 5.9B. Regarding current trading prices, CD5.PA is priced at €86.14, while AEME.PA trades at €72.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas AEME.PA's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is +0.00%, compared to AEME.PA's ROE of N/A. Regarding short-term risk, CD5.PA is more volatile compared to AEME.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check AEME.PA's competition here
CD5.PA vs CW8.PA Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, CW8.PA has a market cap of 5.7B. Regarding current trading prices, CD5.PA is priced at €86.14, while CW8.PA trades at €566.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas CW8.PA's P/E ratio is 24.17. In terms of profitability, CD5.PA's ROE is +0.00%, compared to CW8.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to CW8.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check CW8.PA's competition here
CD5.PA vs IJPA.AS Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, IJPA.AS has a market cap of 5.4B. Regarding current trading prices, CD5.PA is priced at €86.14, while IJPA.AS trades at €52.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas IJPA.AS's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is +0.00%, compared to IJPA.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to IJPA.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check IJPA.AS's competition here
CD5.PA vs UST.PA Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, UST.PA has a market cap of 5.3B. Regarding current trading prices, CD5.PA is priced at €86.14, while UST.PA trades at €81.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas UST.PA's P/E ratio is 34.89. In terms of profitability, CD5.PA's ROE is +0.00%, compared to UST.PA's ROE of N/A. Regarding short-term risk, CD5.PA is more volatile compared to UST.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check UST.PA's competition here
CD5.PA vs PHAU.AS Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, PHAU.AS has a market cap of 5.2B. Regarding current trading prices, CD5.PA is priced at €86.14, while PHAU.AS trades at €265.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas PHAU.AS's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is +0.00%, compared to PHAU.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to PHAU.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check PHAU.AS's competition here
CD5.PA vs VEUR.AS Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, VEUR.AS has a market cap of 5.1B. Regarding current trading prices, CD5.PA is priced at €86.14, while VEUR.AS trades at €42.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas VEUR.AS's P/E ratio is 17.62. In terms of profitability, CD5.PA's ROE is +0.00%, compared to VEUR.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to VEUR.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check VEUR.AS's competition here
CD5.PA vs S500.PA Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, S500.PA has a market cap of 4.9B. Regarding current trading prices, CD5.PA is priced at €86.14, while S500.PA trades at €156.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas S500.PA's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is +0.00%, compared to S500.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to S500.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check S500.PA's competition here
CD5.PA vs KBCA.BR Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, KBCA.BR has a market cap of 4.9B. Regarding current trading prices, CD5.PA is priced at €86.14, while KBCA.BR trades at €63.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas KBCA.BR's P/E ratio is 13.15. In terms of profitability, CD5.PA's ROE is +0.00%, compared to KBCA.BR's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to KBCA.BR. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check KBCA.BR's competition here
CD5.PA vs S500H.PA Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, S500H.PA has a market cap of 4.8B. Regarding current trading prices, CD5.PA is priced at €86.14, while S500H.PA trades at €89.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas S500H.PA's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is +0.00%, compared to S500H.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to S500H.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check S500H.PA's competition here
CD5.PA vs IEMM.AS Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, IEMM.AS has a market cap of 4.6B. Regarding current trading prices, CD5.PA is priced at €86.14, while IEMM.AS trades at €42.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas IEMM.AS's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is +0.00%, compared to IEMM.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to IEMM.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check IEMM.AS's competition here
CD5.PA vs REINA.AS Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, REINA.AS has a market cap of 4.6B. Regarding current trading prices, CD5.PA is priced at €86.14, while REINA.AS trades at €25.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas REINA.AS's P/E ratio is 5.81. In terms of profitability, CD5.PA's ROE is +0.00%, compared to REINA.AS's ROE of +0.12%. Regarding short-term risk, CD5.PA is less volatile compared to REINA.AS. This indicates potentially lower risk in terms of short-term price fluctuations for CD5.PA.Check REINA.AS's competition here
CD5.PA vs EUEA.AS Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, EUEA.AS has a market cap of 4.5B. Regarding current trading prices, CD5.PA is priced at €86.14, while EUEA.AS trades at €54.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas EUEA.AS's P/E ratio is 17.02. In terms of profitability, CD5.PA's ROE is +0.00%, compared to EUEA.AS's ROE of N/A. Regarding short-term risk, CD5.PA is less volatile compared to EUEA.AS. This indicates potentially lower risk in terms of short-term price fluctuations for CD5.PA.Check EUEA.AS's competition here
CD5.PA vs USAC.PA Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, USAC.PA has a market cap of 4.5B. Regarding current trading prices, CD5.PA is priced at €86.14, while USAC.PA trades at €556.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas USAC.PA's P/E ratio is 32.85. In terms of profitability, CD5.PA's ROE is +0.00%, compared to USAC.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to USAC.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check USAC.PA's competition here
CD5.PA vs USA.PA Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, USA.PA has a market cap of 4.3B. Regarding current trading prices, CD5.PA is priced at €86.14, while USA.PA trades at €513.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas USA.PA's P/E ratio is 32.24. In terms of profitability, CD5.PA's ROE is +0.00%, compared to USA.PA's ROE of N/A. Regarding short-term risk, CD5.PA is more volatile compared to USA.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check USA.PA's competition here
CD5.PA vs ALLFG.AS Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, ALLFG.AS has a market cap of 4.3B. Regarding current trading prices, CD5.PA is priced at €86.14, while ALLFG.AS trades at €7.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas ALLFG.AS's P/E ratio is -25.07. In terms of profitability, CD5.PA's ROE is +0.00%, compared to ALLFG.AS's ROE of -0.09%. Regarding short-term risk, CD5.PA is less volatile compared to ALLFG.AS. This indicates potentially lower risk in terms of short-term price fluctuations for CD5.PA.Check ALLFG.AS's competition here
CD5.PA vs 500X.AS Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, 500X.AS has a market cap of 4.2B. Regarding current trading prices, CD5.PA is priced at €86.14, while 500X.AS trades at €38.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas 500X.AS's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is +0.00%, compared to 500X.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to 500X.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check 500X.AS's competition here
CD5.PA vs AUEM.PA Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, AUEM.PA has a market cap of 4.1B. Regarding current trading prices, CD5.PA is priced at €86.14, while AUEM.PA trades at €6.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas AUEM.PA's P/E ratio is 14.32. In terms of profitability, CD5.PA's ROE is +0.00%, compared to AUEM.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to AUEM.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check AUEM.PA's competition here
CD5.PA vs SRIL.AS Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, SRIL.AS has a market cap of 4.1B. Regarding current trading prices, CD5.PA is priced at €86.14, while SRIL.AS trades at €11.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas SRIL.AS's P/E ratio is 26.40. In terms of profitability, CD5.PA's ROE is +0.00%, compared to SRIL.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to SRIL.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check SRIL.AS's competition here
CD5.PA vs C50U.PA Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, C50U.PA has a market cap of 4.1B. Regarding current trading prices, CD5.PA is priced at €86.14, while C50U.PA trades at €162.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas C50U.PA's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is +0.00%, compared to C50U.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is less volatile compared to C50U.PA. This indicates potentially lower risk in terms of short-term price fluctuations for CD5.PA.Check C50U.PA's competition here
CD5.PA vs CACC.PA Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, CACC.PA has a market cap of 4B. Regarding current trading prices, CD5.PA is priced at €86.14, while CACC.PA trades at €38.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas CACC.PA's P/E ratio is 17.19. In terms of profitability, CD5.PA's ROE is +0.00%, compared to CACC.PA's ROE of N/A. Regarding short-term risk, CD5.PA is less volatile compared to CACC.PA. This indicates potentially lower risk in terms of short-term price fluctuations for CD5.PA.Check CACC.PA's competition here
CD5.PA vs CAC.PA Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, CAC.PA has a market cap of 4B. Regarding current trading prices, CD5.PA is priced at €86.14, while CAC.PA trades at €78.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas CAC.PA's P/E ratio is 17.12. In terms of profitability, CD5.PA's ROE is +0.00%, compared to CAC.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is less volatile compared to CAC.PA. This indicates potentially lower risk in terms of short-term price fluctuations for CD5.PA.Check CAC.PA's competition here
CD5.PA vs WSRI.PA Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, WSRI.PA has a market cap of 4B. Regarding current trading prices, CD5.PA is priced at €86.14, while WSRI.PA trades at €103.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas WSRI.PA's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is +0.00%, compared to WSRI.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to WSRI.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check WSRI.PA's competition here
CD5.PA vs MF.PA Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, MF.PA has a market cap of 3.9B. Regarding current trading prices, CD5.PA is priced at €86.14, while MF.PA trades at €92.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas MF.PA's P/E ratio is -31.62. In terms of profitability, CD5.PA's ROE is +0.00%, compared to MF.PA's ROE of -0.08%. Regarding short-term risk, CD5.PA is less volatile compared to MF.PA. This indicates potentially lower risk in terms of short-term price fluctuations for CD5.PA.Check MF.PA's competition here
CD5.PA vs RF.PA Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, RF.PA has a market cap of 3.7B. Regarding current trading prices, CD5.PA is priced at €86.14, while RF.PA trades at €53.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas RF.PA's P/E ratio is -8.92. In terms of profitability, CD5.PA's ROE is +0.00%, compared to RF.PA's ROE of -0.06%. Regarding short-term risk, CD5.PA is less volatile compared to RF.PA. This indicates potentially lower risk in terms of short-term price fluctuations for CD5.PA.Check RF.PA's competition here
CD5.PA vs MSE.PA Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, MSE.PA has a market cap of 3.7B. Regarding current trading prices, CD5.PA is priced at €86.14, while MSE.PA trades at €59.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas MSE.PA's P/E ratio is 16.61. In terms of profitability, CD5.PA's ROE is +0.00%, compared to MSE.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is less volatile compared to MSE.PA. This indicates potentially lower risk in terms of short-term price fluctuations for CD5.PA.Check MSE.PA's competition here
CD5.PA vs AGGD.AS Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, AGGD.AS has a market cap of 3.7B. Regarding current trading prices, CD5.PA is priced at €86.14, while AGGD.AS trades at €5.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas AGGD.AS's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is +0.00%, compared to AGGD.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to AGGD.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check AGGD.AS's competition here
CD5.PA vs ISED.AS Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, ISED.AS has a market cap of 3.7B. Regarding current trading prices, CD5.PA is priced at €86.14, while ISED.AS trades at €7.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas ISED.AS's P/E ratio is 21.78. In terms of profitability, CD5.PA's ROE is +0.00%, compared to ISED.AS's ROE of N/A. Regarding short-term risk, CD5.PA is more volatile compared to ISED.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check ISED.AS's competition here
CD5.PA vs IDSE.AS Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, IDSE.AS has a market cap of 3.6B. Regarding current trading prices, CD5.PA is priced at €86.14, while IDSE.AS trades at €139.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas IDSE.AS's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is +0.00%, compared to IDSE.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is less volatile compared to IDSE.AS. This indicates potentially lower risk in terms of short-term price fluctuations for CD5.PA.Check IDSE.AS's competition here
CD5.PA vs GLUH.AS Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, GLUH.AS has a market cap of 3.6B. Regarding current trading prices, CD5.PA is priced at €86.14, while GLUH.AS trades at €4.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas GLUH.AS's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is +0.00%, compared to GLUH.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to GLUH.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check GLUH.AS's competition here
CD5.PA vs VERX.AS Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, VERX.AS has a market cap of 3.6B. Regarding current trading prices, CD5.PA is priced at €86.14, while VERX.AS trades at €42.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas VERX.AS's P/E ratio is 17.13. In terms of profitability, CD5.PA's ROE is +0.00%, compared to VERX.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to VERX.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check VERX.AS's competition here
CD5.PA vs ROLA.AS Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, ROLA.AS has a market cap of 3.6B. Regarding current trading prices, CD5.PA is priced at €86.14, while ROLA.AS trades at €65.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas ROLA.AS's P/E ratio is 6.52. In terms of profitability, CD5.PA's ROE is +0.00%, compared to ROLA.AS's ROE of N/A. Regarding short-term risk, CD5.PA is more volatile compared to ROLA.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check ROLA.AS's competition here
CD5.PA vs AEEM.PA Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, AEEM.PA has a market cap of 3.6B. Regarding current trading prices, CD5.PA is priced at €86.14, while AEEM.PA trades at €5.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas AEEM.PA's P/E ratio is 15.39. In terms of profitability, CD5.PA's ROE is +0.00%, compared to AEEM.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to AEEM.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check AEEM.PA's competition here
CD5.PA vs C50.PA Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, C50.PA has a market cap of 3.5B. Regarding current trading prices, CD5.PA is priced at €86.14, while C50.PA trades at €139.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas C50.PA's P/E ratio is 16.55. In terms of profitability, CD5.PA's ROE is +0.00%, compared to C50.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is less volatile compared to C50.PA. This indicates potentially lower risk in terms of short-term price fluctuations for CD5.PA.Check C50.PA's competition here
CD5.PA vs TKO.PA Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, TKO.PA has a market cap of 3.5B. Regarding current trading prices, CD5.PA is priced at €86.14, while TKO.PA trades at €20.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas TKO.PA's P/E ratio is 23.72. In terms of profitability, CD5.PA's ROE is +0.00%, compared to TKO.PA's ROE of +0.05%. Regarding short-term risk, CD5.PA is more volatile compared to TKO.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check TKO.PA's competition here
CD5.PA vs EHYD.AS Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, EHYD.AS has a market cap of 3.5B. Regarding current trading prices, CD5.PA is priced at €86.14, while EHYD.AS trades at €4.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas EHYD.AS's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is +0.00%, compared to EHYD.AS's ROE of N/A. Regarding short-term risk, CD5.PA is more volatile compared to EHYD.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check EHYD.AS's competition here
CD5.PA vs EHYA.AS Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, EHYA.AS has a market cap of 3.5B. Regarding current trading prices, CD5.PA is priced at €86.14, while EHYA.AS trades at €5.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas EHYA.AS's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is +0.00%, compared to EHYA.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to EHYA.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check EHYA.AS's competition here
CD5.PA vs ICHD.AS Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, ICHD.AS has a market cap of 3.5B. Regarding current trading prices, CD5.PA is priced at €86.14, while ICHD.AS trades at €5.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas ICHD.AS's P/E ratio is 13.96. In terms of profitability, CD5.PA's ROE is +0.00%, compared to ICHD.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to ICHD.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check ICHD.AS's competition here
CD5.PA vs ICHN.AS Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, ICHN.AS has a market cap of 3.5B. Regarding current trading prices, CD5.PA is priced at €86.14, while ICHN.AS trades at €5.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas ICHN.AS's P/E ratio is 14.12. In terms of profitability, CD5.PA's ROE is +0.00%, compared to ICHN.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to ICHN.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check ICHN.AS's competition here
CD5.PA vs BREB.BR Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, BREB.BR has a market cap of 3.2B. Regarding current trading prices, CD5.PA is priced at €86.14, while BREB.BR trades at €110.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas BREB.BR's P/E ratio is 7.84. In terms of profitability, CD5.PA's ROE is +0.00%, compared to BREB.BR's ROE of +0.10%. Regarding short-term risk, CD5.PA is less volatile compared to BREB.BR. This indicates potentially lower risk in terms of short-term price fluctuations for CD5.PA.Check BREB.BR's competition here
CD5.PA vs SEMD.AS Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, SEMD.AS has a market cap of 3.2B. Regarding current trading prices, CD5.PA is priced at €86.14, while SEMD.AS trades at €5.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas SEMD.AS's P/E ratio is 16.53. In terms of profitability, CD5.PA's ROE is +0.00%, compared to SEMD.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to SEMD.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check SEMD.AS's competition here
CD5.PA vs EEUE.PA Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, EEUE.PA has a market cap of 3.2B. Regarding current trading prices, CD5.PA is priced at €86.14, while EEUE.PA trades at €17.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas EEUE.PA's P/E ratio is 18.25. In terms of profitability, CD5.PA's ROE is +0.00%, compared to EEUE.PA's ROE of N/A. Regarding short-term risk, CD5.PA is more volatile compared to EEUE.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check EEUE.PA's competition here
CD5.PA vs WESE.PA Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, WESE.PA has a market cap of 3.2B. Regarding current trading prices, CD5.PA is priced at €86.14, while WESE.PA trades at €72.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas WESE.PA's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is +0.00%, compared to WESE.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to WESE.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check WESE.PA's competition here
CD5.PA vs CB3.PA Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, CB3.PA has a market cap of 3.1B. Regarding current trading prices, CD5.PA is priced at €86.14, while CB3.PA trades at €220.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas CB3.PA's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is +0.00%, compared to CB3.PA's ROE of N/A. Regarding short-term risk, CD5.PA is more volatile compared to CB3.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check CB3.PA's competition here
CD5.PA vs IMBE.AS Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, IMBE.AS has a market cap of 3.1B. Regarding current trading prices, CD5.PA is priced at €86.14, while IMBE.AS trades at €4.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas IMBE.AS's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is +0.00%, compared to IMBE.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to IMBE.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check IMBE.AS's competition here
CD5.PA vs SGLU.AS Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, SGLU.AS has a market cap of 2.9B. Regarding current trading prices, CD5.PA is priced at €86.14, while SGLU.AS trades at €4.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas SGLU.AS's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is +0.00%, compared to SGLU.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to SGLU.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check SGLU.AS's competition here
CD5.PA vs IGLE.AS Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, IGLE.AS has a market cap of 2.9B. Regarding current trading prices, CD5.PA is priced at €86.14, while IGLE.AS trades at €4.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas IGLE.AS's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is +0.00%, compared to IGLE.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to IGLE.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check IGLE.AS's competition here
CD5.PA vs EXCH.AS Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, EXCH.AS has a market cap of 2.8B. Regarding current trading prices, CD5.PA is priced at €86.14, while EXCH.AS trades at €5.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas EXCH.AS's P/E ratio is 16.44. In terms of profitability, CD5.PA's ROE is +0.00%, compared to EXCH.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to EXCH.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check EXCH.AS's competition here
CD5.PA vs ESE.PA Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, ESE.PA has a market cap of 2.8B. Regarding current trading prices, CD5.PA is priced at €86.14, while ESE.PA trades at €27.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas ESE.PA's P/E ratio is 27.24. In terms of profitability, CD5.PA's ROE is +0.00%, compared to ESE.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to ESE.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check ESE.PA's competition here
CD5.PA vs GEMU.PA Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, GEMU.PA has a market cap of 2.6B. Regarding current trading prices, CD5.PA is priced at €86.14, while GEMU.PA trades at €9.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas GEMU.PA's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is +0.00%, compared to GEMU.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to GEMU.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check GEMU.PA's competition here
CD5.PA vs EUSRI.PA Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, EUSRI.PA has a market cap of 2.5B. Regarding current trading prices, CD5.PA is priced at €86.14, while EUSRI.PA trades at €85.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas EUSRI.PA's P/E ratio is 21.79. In terms of profitability, CD5.PA's ROE is +0.00%, compared to EUSRI.PA's ROE of N/A. Regarding short-term risk, CD5.PA is more volatile compared to EUSRI.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check EUSRI.PA's competition here
CD5.PA vs TDIV.AS Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, TDIV.AS has a market cap of 2.5B. Regarding current trading prices, CD5.PA is priced at €86.14, while TDIV.AS trades at €43.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas TDIV.AS's P/E ratio is 11.40. In terms of profitability, CD5.PA's ROE is +0.00%, compared to TDIV.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to TDIV.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check TDIV.AS's competition here
CD5.PA vs TNOW.PA Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, TNOW.PA has a market cap of 2.4B. Regarding current trading prices, CD5.PA is priced at €86.14, while TNOW.PA trades at €881.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas TNOW.PA's P/E ratio is 41.55. In terms of profitability, CD5.PA's ROE is +0.00%, compared to TNOW.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to TNOW.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check TNOW.PA's competition here
CD5.PA vs SUOA.AS Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, SUOA.AS has a market cap of 2.4B. Regarding current trading prices, CD5.PA is priced at €86.14, while SUOA.AS trades at €5.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas SUOA.AS's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is +0.00%, compared to SUOA.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to SUOA.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check SUOA.AS's competition here
CD5.PA vs ANX.PA Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, ANX.PA has a market cap of 2.4B. Regarding current trading prices, CD5.PA is priced at €86.14, while ANX.PA trades at €229.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas ANX.PA's P/E ratio is 34.50. In terms of profitability, CD5.PA's ROE is +0.00%, compared to ANX.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to ANX.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check ANX.PA's competition here
CD5.PA vs EPAB.PA Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, EPAB.PA has a market cap of 2.4B. Regarding current trading prices, CD5.PA is priced at €86.14, while EPAB.PA trades at €35.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas EPAB.PA's P/E ratio is 17.30. In terms of profitability, CD5.PA's ROE is +0.00%, compared to EPAB.PA's ROE of N/A. Regarding short-term risk, CD5.PA is more volatile compared to EPAB.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check EPAB.PA's competition here
CD5.PA vs BNKE.PA Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, BNKE.PA has a market cap of 2.3B. Regarding current trading prices, CD5.PA is priced at €86.14, while BNKE.PA trades at €255.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas BNKE.PA's P/E ratio is 9.52. In terms of profitability, CD5.PA's ROE is +0.00%, compared to BNKE.PA's ROE of N/A. Regarding short-term risk, CD5.PA is less volatile compared to BNKE.PA. This indicates potentially lower risk in terms of short-term price fluctuations for CD5.PA.Check BNKE.PA's competition here
CD5.PA vs IUHE.AS Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, IUHE.AS has a market cap of 2.3B. Regarding current trading prices, CD5.PA is priced at €86.14, while IUHE.AS trades at €6.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas IUHE.AS's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is +0.00%, compared to IUHE.AS's ROE of N/A. Regarding short-term risk, CD5.PA is more volatile compared to IUHE.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check IUHE.AS's competition here
CD5.PA vs TI5A.AS Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, TI5A.AS has a market cap of 2.3B. Regarding current trading prices, CD5.PA is priced at €86.14, while TI5A.AS trades at €112.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas TI5A.AS's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is +0.00%, compared to TI5A.AS's ROE of N/A. Regarding short-term risk, CD5.PA is more volatile compared to TI5A.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check TI5A.AS's competition here
CD5.PA vs ANTIN.PA Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, ANTIN.PA has a market cap of 2.2B. Regarding current trading prices, CD5.PA is priced at €86.14, while ANTIN.PA trades at €12.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas ANTIN.PA's P/E ratio is 16.70. In terms of profitability, CD5.PA's ROE is +0.00%, compared to ANTIN.PA's ROE of +0.27%. Regarding short-term risk, CD5.PA is less volatile compared to ANTIN.PA. This indicates potentially lower risk in terms of short-term price fluctuations for CD5.PA.Check ANTIN.PA's competition here
CD5.PA vs USRI.PA Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, USRI.PA has a market cap of 2.1B. Regarding current trading prices, CD5.PA is priced at €86.14, while USRI.PA trades at €102.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas USRI.PA's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is +0.00%, compared to USRI.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to USRI.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check USRI.PA's competition here
CD5.PA vs PEUG.PA Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, PEUG.PA has a market cap of 1.9B. Regarding current trading prices, CD5.PA is priced at €86.14, while PEUG.PA trades at €77.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas PEUG.PA's P/E ratio is 13.17. In terms of profitability, CD5.PA's ROE is +0.00%, compared to PEUG.PA's ROE of +0.03%. Regarding short-term risk, CD5.PA is less volatile compared to PEUG.PA. This indicates potentially lower risk in terms of short-term price fluctuations for CD5.PA.Check PEUG.PA's competition here
CD5.PA vs ACWI.PA Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, ACWI.PA has a market cap of 1.9B. Regarding current trading prices, CD5.PA is priced at €86.14, while ACWI.PA trades at €490.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas ACWI.PA's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is +0.00%, compared to ACWI.PA's ROE of N/A. Regarding short-term risk, CD5.PA is more volatile compared to ACWI.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check ACWI.PA's competition here
CD5.PA vs CMUD.PA Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, CMUD.PA has a market cap of 1.9B. Regarding current trading prices, CD5.PA is priced at €86.14, while CMUD.PA trades at €67.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas CMUD.PA's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is +0.00%, compared to CMUD.PA's ROE of N/A. Regarding short-term risk, CD5.PA is more volatile compared to CMUD.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check CMUD.PA's competition here
CD5.PA vs DHYE.AS Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, DHYE.AS has a market cap of 1.9B. Regarding current trading prices, CD5.PA is priced at €86.14, while DHYE.AS trades at €5.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas DHYE.AS's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is +0.00%, compared to DHYE.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to DHYE.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check DHYE.AS's competition here
CD5.PA vs PHAG.AS Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, PHAG.AS has a market cap of 1.8B. Regarding current trading prices, CD5.PA is priced at €86.14, while PHAG.AS trades at €30.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas PHAG.AS's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is +0.00%, compared to PHAG.AS's ROE of N/A. Regarding short-term risk, CD5.PA is more volatile compared to PHAG.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check PHAG.AS's competition here
CD5.PA vs EGOV.PA Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, EGOV.PA has a market cap of 1.8B. Regarding current trading prices, CD5.PA is priced at €86.14, while EGOV.PA trades at €49.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas EGOV.PA's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is +0.00%, compared to EGOV.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to EGOV.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check EGOV.PA's competition here
CD5.PA vs MUSD.AS Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, MUSD.AS has a market cap of 1.8B. Regarding current trading prices, CD5.PA is priced at €86.14, while MUSD.AS trades at €8.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas MUSD.AS's P/E ratio is 28.43. In terms of profitability, CD5.PA's ROE is +0.00%, compared to MUSD.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to MUSD.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check MUSD.AS's competition here
CD5.PA vs PABW.PA Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, PABW.PA has a market cap of 1.8B. Regarding current trading prices, CD5.PA is priced at €86.14, while PABW.PA trades at €79.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas PABW.PA's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is +0.00%, compared to PABW.PA's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to PABW.PA. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check PABW.PA's competition here
CD5.PA vs CYBA.AS Comparison July 2025
CD5.PA plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CD5.PA stands at 3.5B. In comparison, CYBA.AS has a market cap of 1.8B. Regarding current trading prices, CD5.PA is priced at €86.14, while CYBA.AS trades at €6.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CD5.PA currently has a P/E ratio of 16.65, whereas CYBA.AS's P/E ratio is N/A. In terms of profitability, CD5.PA's ROE is +0.00%, compared to CYBA.AS's ROE of +0.00%. Regarding short-term risk, CD5.PA is more volatile compared to CYBA.AS. This indicates potentially higher risk in terms of short-term price fluctuations for CD5.PA.Check CYBA.AS's competition here